Cotinga Pharmaceuticals

COT.V is a biopharmaceutical company that is focused on developing treatments for various ranges of cancer. Read more

Alison Silva's photo - President & CEO of Cotinga Pharmaceuticals

President & CEO

Alison Silva

CEO Approval Rating

70/100

Founded:

1999

Status:

PublicIndependent CompanyTMX Group - Toronto Stock ExchangeCOT

Annual Revenue
Employees
Sector

- -

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Quarterly and Annual Revenue

Coming soon for Cotinga Pharmaceuticals!

Annual Revenue

Cotinga Pharmaceuticals Acquisitions

No recent acquisitions found related to Cotinga Pharmaceuticals

Cotinga Pharmaceuticals Funding History

Since Cotinga Pharmaceuticals was founded in 1999, it has participated in 1 round of funding. In total Cotinga Pharmaceuticals has raised $1.6M. Cotinga Pharmaceuticals' funding round was on May 2018 for a total of $1.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
May 2018
$1.6M
-

Since Cotinga Pharmaceuticals was founded in 1999, it has participated in 1 round of funding. In total Cotinga Pharmaceuticals has raised $1.6M. Cotinga Pharmaceuticals' funding round was on May 2018 for a total of $1.6M

Cotinga Pharmaceuticals Investments

No recent investments found related to Cotinga Pharmaceuticals

Cotinga Pharmaceuticals News

October 2, 2018BioPortfolio

Cotinga Pharmaceuticals Inc COT Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 17092018 Prices from USD $250

SummaryCotinga Pharmaceuticals Inc Cotinga is a biopharmaceutical company that develops targeted ther... See more »
August 29, 2018Silver Investing News

Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results

Cotinga Pharmaceuticals (TSXV:COT) has announced its financial and operating results for Q4 and full ... See more »
August 24, 2018BioPortfolio

Cotinga Pharmaceuticals Inc COT Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250

SummaryCotinga Pharmaceuticals Inc Cotinga is a biopharmaceutical company that develops targeted ther... See more »
May 24, 20184-traders

Pharma Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program

(4-traders.com) Press Release COTINGA PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF SIGNIFICANT PROTOCOL... See more »
May 17, 20184-traders

Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting

(4-traders.com) Press Release COTINGA PHARMACEUTICALS ANNOUNCES PRESENTATION ON COTI-2 AT THE 2018 AM... See more »
May 4, 20184-traders

Closes $2 Million Private Placement

(4-traders.com) Press Release COTINGA PHARMACEUTICALS CLOSES $2.0M PRIVATE PLACEMENT Funds to support... See more »

Cotinga Pharmaceuticals Press Releases

May 8, 2019GlobalNewswire

Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

Cohort two fully enrolled in a wide range of cancer typesCohort two fully enrolled in a wide range of... See more »
April 5, 2019GlobalNewswire

Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results

TORONTO and BOSTON, April 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT... See more »
March 19, 2019GlobeNewswire

Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering

Highlighted progress and continued commitment to advancing the clinical development of lead asset COT... See more »
February 26, 2019GlobeNewswire

Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased doseIndep... See more »
January 29, 2019GlobeNewswire

Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2

TORONTO and BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT)... See more »
January 15, 2019GlobalNewswire

Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2

Cohort 1 of COTI-2 plus cisplatin combination trial is fully enrolled at MD AndersonCohort 1 of COTI-... See more »
January 3, 2019GlobalNewswire

Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results

TORONTO and BOSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT;... See more »

Social Media

Cotinga Pharmaceuticals Headquarters

127 Main Street

Boston, Massachusetts02129

1-800-798-8680

Driving Directions »

Trending Companies

Cotinga Pharmaceuticals Summary

ABOUT

Overview

COT.V is a biopharmaceutical company that is focused on developing treatments for various ranges of cancer. Cotinga Pharmaceuticals was founded in 1999. Cotinga Pharmaceuticals' headquarters is located in Boston, Massachusetts, USA 02129. It has raise...

CEO

Cotinga Pharmaceuticals's President & CEO, Alison Silva, currently has an approval rating of 70%. Cotinga Pharmaceuticals's primary competitors are

Frequently Asked Questions about Cotinga Pharmaceuticals

  1. When was Cotinga Pharmaceuticals founded?

    Cotinga Pharmaceuticals was founded in 1999
  2. Who is Cotinga Pharmaceuticals's CEO?

    Cotinga Pharmaceuticals's CEO is Alison Silva
  3. How much revenue does Cotinga Pharmaceuticals generate?

    Cotinga Pharmaceuticals generates $ < 1M in revenue
  1. How much funding does Cotinga Pharmaceuticals have?

    Cotinga Pharmaceuticals has historically raised $1.6M in funding
  2. Where is Cotinga Pharmaceuticals's headquarters?

    Cotinga Pharmaceuticals's headquarters is in Boston Massachusetts, USA
  3. How many employees does Cotinga Pharmaceuticals have?

    Cotinga Pharmaceuticals has 10 employees